2017
DOI: 10.14309/00000434-201710001-02194
|View full text |Cite
|
Sign up to set email alerts
|

Polycystic Ovarian Syndrome, Hepatocellular Adenoma, Oral Contraceptive Pills: A Clinical Conundrum

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Like non-PCOS populations, cessation of CHCs remains the first step in HCA management. Although higher-dose progestins used for noncontraceptive purposes may have a small amount of estrogen conversion, lower doses found in progestin-only contraceptives can be safely used in patients with HCAs (5–7). Such options include progestin-only pills, the hormonal intrauterine device, subcutaneous implant, and depo-medroxyprogesterone injection (8).…”
Section: Management In Polycystic Ovary Syndromementioning
confidence: 99%
“…Like non-PCOS populations, cessation of CHCs remains the first step in HCA management. Although higher-dose progestins used for noncontraceptive purposes may have a small amount of estrogen conversion, lower doses found in progestin-only contraceptives can be safely used in patients with HCAs (5–7). Such options include progestin-only pills, the hormonal intrauterine device, subcutaneous implant, and depo-medroxyprogesterone injection (8).…”
Section: Management In Polycystic Ovary Syndromementioning
confidence: 99%